

contengono il 20% in meno di principio attivo!”.

Anche perché se abbiamo impiegato 15 anni per capire i farmaci equivalenti, e non ci siamo ancora arrivati, come faremo per i biosimilari?

Ma questa è un'altra storia...

BIBLIOGRAFIA

1. “Question & Answers On The Bioavailability And Bioequivalence Guideline”, London, 27 July 2006 (EMA/CHMP/EWP/40326/2006), Guideline on the investigation of bioequivalence: revision 1:

[http://www.ema.europa.eu/\[...\]/Scientific_guideline/2010/01/WC500070039](http://www.ema.europa.eu/[...]/Scientific_guideline/2010/01/WC500070039).

- pdf
2. <http://farmacologiasif.unito.it/search.htm>
3. Chenu F, Batten LA, Zernig G, et al., Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. *J Clin Psychiatry* 70, 958-966, 2009.
4. Del Tacca M, Pasqualetti G, Di Paolo A, et al. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations: a post-marketing clinical study on healthy volunteers. *Br J Clin Pharmacol* 68, 34-42, 2009.
5. La prescription en DCI a des limites pharmaco-therapeutiques. *La Revue Prescrire* 2002; 234: 893-5.
6. Sy FZ, Moving from A to Z: successful implementation of a statin switch program by a large physician group *Am J Manag Care*. 2009; 15 (4): 233-40.
7. Davit BM, Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration. *Ann Pharmacother* 2009; 43: 1583-97.
8. Kesselheim AS, Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis. *JAMA*. 2008; 300 (21): 2514-2526.
9. Briesacher BA, Medication Adherence and Use of Generic Drug Therapies. *Am J Manag Care*. 2009; 15 (7): 450-456.